Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androxal QT/QTc study in healthy males
NCT02117830Phase 1Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of enclomiphene in secondary hypogonadism (HH) (4 arms), sponsored by Repros Therapeutics Inc. Primary endpoint: Placebo-subtracted change of the QTc interval from Baseline at 64 days. Started Apr 2014; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT02117830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117830.